From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Do Patients with Mild Asthma Need Daily Inhaled Steroids?

Maybe not. Intermittent steroid use to treat worsening symptoms might be enough.

According to national guidelines, mild persistent asthma is defined by a need for ß-agonist treatment more than 2 days per week (but less than daily), asthma-related nighttime awakenings more than twice per month (but not more than once weekly), or spirometric criteria (http://www.nhlbi.nih.gov/health/prof/lung/asthma/practgde/practgde.pdf). Daily inhaled corticosteroids are recommended for such patients, but is such treatment really necessary?

In this partially industry-supported, multicenter trial, 225 adults with mild persistent asthma were randomized to receive twice-daily inhaled budesonide plus placebo tablets, twice-daily oral zafirlukast plus placebo inhaler, or twice-daily double placebo. Patients used inhaled albuterol as needed; in addition, all were instructed in self-treatment with a 10-day course of inhaled high-dose budesonide or a 5-day course of oral prednisone for worsening symptoms.

After 1 year, the groups did not differ significantly in the primary outcome (change from baseline in morning peak expiratory flow) or in the number of asthma exacerbations warranting prednisone treatment. Patients in the twice-daily budesonide group had significantly more symptom-free days per 2-week period than patients in the other two groups (mean, 10 vs. 9 vs. 9 days), but quality-of-life scores were similar in all groups.

Comment: This trial suggests that adults with mild persistent asthma do not necessarily need daily preventive treatment. Patients in the double-placebo group (who received only intermittent therapy to treat worsening symptoms) did nearly as well as those who received daily inhaled steroid, and just as well as those who received daily zafirlukast. The authors believe, however, that longer and larger studies should be done before guidelines are changed.

— Allan S. Brett, MD

Published in Journal Watch General Medicine April 22, 2005

Citation(s):

Boushey HA et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005 Apr 14; 352:1519-28.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2005. Massachusetts Medical Society. All rights reserved.